65,437 trials
Actinic Keratoses
Primary: Number of Participants With Complete Clearance of AK Lesions — 57; 49; 10 participants
Actinic Keratosis
Primary: Number of Participants With Complete Clearance of AK Lesions — 55; 41; 9 participants
Chemotherapy-Induced Nausea and Vomiting
Primary: Plasma Area Under The Concentration Versus Time Curve (AUC(0-infinity)) For Ondansetron — 257.8; 262.6 ng*hr/mL
Pain, Postoperative
Primary: Average Numeric Pain Rating Score (NPRS) Over 48 Hours After Bunionectomy — 3.3; 5.7 units on a scale
Asthma, Exercise-Induced
Primary: Maximum Percent Fall in FEV1 After Exercise Challenge at 2 Hours Postdose Compared With Pre-exercise Baseline in Patients With Exercise-induced Bronchospasm (EIB)…
Asthma
Primary: Number of Clinical Adverse Experiences (CAEs) Reported by Patients With up to 52 Weeks of Treatment — 31; 156; 1; 2 Participants
Chronic Conditions · Arthritis · Diabetes
Primary: Physical Functioning Inventory (PFI) — 5.50; 2.96 units on a scale
Asthma
Primary: Number of Clinical Adverse Experiences (CAEs) Reported by Patients During the 6-weeks of Treatment — 62; 132; 19; 43 Participants
Type 2 Diabetes Mellitus
Primary: Hemoglobin A1C (A1C) at Week 18 — -0.73; -0.79; -0.22 Percent of glycosylated hemoglobin (A1C) — p=<=0.001
Cervical Cancer · Endometrial Cancer · Ovarian Cancer
Primary: Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC) — 5 Participants
Reflux Esophagitis
Primary: Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period. — 174; 166; 156 Participants
Sleep-Disordered Breathing · Obstructive Sleep Apnea · Sleep Apnea
Primary: Sensitivity and Specificity Data of the Saturation Pattern Detection (SPD) Feature as a Predictor of Repetitive Reductions in Airflow (RRiA). — 0.820; 0.897 Ratio
Diabetes
Primary: Number of Duplicate Capillary Results Within +/- 15mg/dL or +/- 20% of Laboratory Glucose Method — 142; 143 number of capillary results (n=79x2)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over the 2-week Treatment Period — -0.38; -0.47; -0.29 Scores on a scale
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.26; -0.48; -0.52; -0.58 Units on a Scale